Last updated: Nov 19, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07715903 | 1 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | Proteasome -- proteasome inhibitor (carfilzomib) |
| NCT06903273 | 2 | Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma | PD-1 -- immune checkpoint inhibitor (monoclonal antibody) |
| NCT07829874 | 2 | Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer. | PD-1 + CTLA-4 -- bispecific antibody; VEGFR + other kinases -- multi-kinase inhibitor (TKI) |
| NCT07938021 | 2 | HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers | HER2 -- anti-HER2 monoclonal antibody (trastuzumab/pertuzumab) combined with PD-1 immune checkpoint blockade (serplulimab) and HLX22 (Unknown mechanism) |
| NCT07938645 | 2 | PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency Genes | PARP1/2 -- PARP inhibitor combined with PD-L1 immune checkpoint blockade (PARP inhibitor + anti-PD-L1 immunotherapy) |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 14 |
| Shanghai Zhongshan Hospital | 10 |
| Tianjin Medical University Cancer Institute and Hospital | 8 |
| Peking Union Medical College Hospital | 8 |
| M.D. Anderson Cancer Center | 6 |
Countries/regions with the most active trial sites for cholangiocarcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
| Nov 23, 2026 | NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | Proteasome -- proteasome inhibitor (carfilzomib) |
| Nov 2026 | NCT07738939 | IKS04 Regimen in Advanced Solid Tumors That Express CA242 | CA242 -- antibody-drug conjugate (ADC) |
| Sep 15, 2026 | NCT07632235 | A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | COX-2 -- selective inhibition (NSAID); PD-1 -- immune checkpoint blockade (monoclonal antibody) |
| Sep 2026 | NCT07796997 | GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy | Glucocorticoid receptor -- anti-inflammatory and immunosuppressive effects (steroid hormone) |
| May 2026 | NCT07614061 | Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer | CD160 -- autologous antigen-specific T-cell therapy |
| Mar 27, 2026 | NCT07107750 | Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer | IRAK4 -- small molecule inhibitor (Emavusertib) + chemotherapy (Gemcitabine, Cisplatin) + PD-L1 -- immune checkpoint inhibitor (Durvalumab) |
| Mar 2, 2026 | NCT07641036 | Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer | HER2 + CEACAM5 -- dual-target chimeric antigen receptor natural killer cells (CAR-NK) |
You've seen the cholangiocarcinoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.